Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ12565MR)

This product GTTS-WQ12565MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Felinized
RefSeq	XM_004001117.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	100144611
UniProt ID	A0A337SBN0

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12565MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3817MR	IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	BB-10901
GTTS-WQ6825MR	IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	DSTP-3086S
GTTS-WQ6426MR	IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CT-P22
GTTS-WQ5911MR	IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	CIM 331
GTTS-WQ12277MR	IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	MSB-0010718C
GTTS-WQ15608MR	IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	VAL-1221
GTTS-WQ8349MR	IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	hPAM4
GTTS-WQ4579MR	IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	BMS-986004

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST